NIH Highlighted Topic: Catalyzing Interdisciplinary Research on HIV-Associated Co-occurring Conditions
Executive Summary
The National Institutes of Health has published a Highlighted Topic titled "Catalyzing Interdisciplinary Research on HIV-Associated Co-occurring Conditions." Twelve NIH Institutes award grants under it and five additional offices participate without awarding, making this one of the broadest cross-NIH topics published this cycle. The scientific premise is that antiretroviral therapy has turned HIV into a manageable chronic condition, but people with HIV now face early onset and elevated risk of comorbidities, treatment-related adverse effects, and interconnected medical, psychosocial, and structural challenges that disease-specific research models handle poorly.
For a small business, the practical translation is this: there is no new application portal and no new deadline attached to this topic. A Highlighted Topic is a demand signal, not a Notice of Funding Opportunity. You capture the funding by submitting to the NIH SBIR or STTR parent announcement, requesting assignment to one of the twelve awarding Institutes, and aligning your Specific Aims to that Institute's stated interests.
Two things about this topic deserve to be said plainly before you invest a cycle in it. First, a substantial share of the published language describes work that is not a small business fit: cohort analysis, mechanistic basic science, academically led community-based trials, and health disparities characterization. Those belong in R01 and related mechanisms. The slices that are genuinely SBIR-fundable are narrower and named below. Second, two of the twelve awarding Institutes, NIAMS and NIDCR, will not accept clinical trial applications under either parent announcement, even though both explicitly ask for research that develops and tests interventions. Two more, NIAID and NIDDK, accept clinical trials under SBIR but not under STTR. Getting this wrong makes an application non-responsive and unreviewed regardless of its scientific merit.
The topic was posted on September 1, 2026 and expires on July 28, 2028, which is a shorter window than the standard two years and eliminates the September 2028 cycle. The realistic competing cycles run from January 5, 2027 through April 5, 2028.
If you build diagnostics or screening tools for subclinical comorbidity, therapeutics or biologics for HIV-associated disease, medication optimization and polypharmacy tools, care coordination or clinical decision support software, point-of-care coinfection testing, or integrated behavioral health delivery platforms, there is real money here across multiple Institutes.
At a Glance
Topic title: Catalyzing Interdisciplinary Research on HIV-Associated Co-occurring Conditions
Issuing agency: National Institutes of Health, U.S. Department of Health and Human Services
Awarding Institutes: NCCIH, NCI, NHLBI, NIA, NIAAA, NIAID, NIAMS, NICHD, NIDA, NIDCR, NIDDK, and NIMH
Non-awarding participating offices: OAR, OBSSR, ODP, ORWH, and THRO
Central scientific contact: Office of AIDS Research, OARinfo@nih.gov
Type: NIH Highlighted Topic. This is not a Notice of Funding Opportunity.
Post date: September 1, 2026
Expiration date: July 28, 2028. Note this is short of the usual two-year window.
Recommended small business mechanism: NIH SBIR (R43 and R44) or NIH STTR (R41 and R42) parent announcement
Current parent announcements: PA-27-100 for SBIR, PA-27-102 for STTR, PA-27-101 for the Phase IIB Strategic Breakthrough Award, and PAR-27-098 for the Commercialization Readiness Pilot
Standard annual due dates: January 5, April 5, and September 5. HHS SBIR and STTR applications are not accepted on the AIDS and AIDS-related due dates, so the standard dates apply here despite the HIV subject matter.
SBA statutory guidelines this cycle: $323,090 Phase I, $2,153,927 Phase II, $4,191,495 CRP
Institute headroom: several participating Institutes list Phase I limits above the statutory guideline, up to $700,000, and Phase II limits up to $2.5 million or $3 million. Limits differ by Institute and must be confirmed.
Clinical trials: not accepted by NIAMS or NIDCR under either parent announcement. Not accepted by NIAID or NIDDK under STTR, though both accept them under SBIR.
Cost share: none for Phase I or Phase II. Phase IIB requires 100 percent third-party matching funds.
Equity dilution: none. This is non-dilutive federal funding.
Profit or fee: allowable, must be in the budget at submission, and normally will not exceed 7 percent of total costs
Strongest funding signals: NIDA states both that it may dedicate available funds and that it may give special consideration. NHLBI states it may dedicate available funds. NCCIH and NIDCR each state they may give special consideration.
Broader initiative alignment: Make America Healthy Again initiative, with eight named component efforts
What This Opportunity Actually Is
An NIH Highlighted Topic is a published statement of scientific interest from one or more NIH Institutes, Centers, and Offices. It tells the research community that an area of science is a priority without creating a separate funding announcement, deadline, or review process. There is no topic-specific number to search on Grants.gov, and applications are not scored against other applications to the topic.
What it does do is identify which Institutes are receptive, which determines your assignment request and your program officer conversations; supply the vocabulary program staff already use internally, which your Specific Aims should mirror; and in four cases here create an explicit stated advantage. NIDA is the only participating Institute that made both available statements, saying it may dedicate available funds to this topic area depending on the availability of funds, the number of meritorious applications, and competing priorities, and separately that it may give special consideration to meritorious applications in the topic area. NHLBI made the funds statement. NCCIH and NIDCR each made the special consideration statement. The remaining eight awarding Institutes made neither.
That distribution is worth reading carefully. It does not mean the other eight will not fund this work. It does mean four Institutes went on record and eight did not, which is the closest thing to a competitive signal a Highlighted Topic provides.
Is This Topic a Fit for a Small Business?
This topic is less small-business-native than most NIH Highlighted Topics, and an honest read saves cycles.
The topic language repeatedly emphasizes interdisciplinary collaborative science, multidisciplinary teams with multiple Program Directors and Principal Investigators holding complementary expertise, meaningful community engagement, cross-NIH alignment, and use of existing NIH resources. Those are hallmarks of investigator-initiated academic research, and much of what is described is best pursued through R01, R34, or cooperative agreement mechanisms rather than SBIR or STTR.
Work in this topic that is a poor small business fit: secondary analysis of existing cohorts; epidemiological characterization of comorbidity burden; mechanistic basic science with no identified product; health disparities documentation; academically led community-based behavioral trials where the small business would be a subcontractor rather than the developer of a commercial product.
Work in this topic that is a genuine small business fit:
Screening and diagnostics for subclinical disease. NHLBI explicitly asks for novel methods to detect subclinical HIV-related heart, lung, blood, and sleep conditions. NCI asks for new biomarkers and diagnostics. NIDCR asks for early cancer detection in the oral and craniofacial complex. This is the clearest product lane in the entire topic.
Therapeutics and biologics. NCI asks for therapeutics improving prevention, diagnosis, treatment, and outcomes in people with HIV. NIAAA asks for biomedical approaches to restore alcohol-induced organ dysfunction. NIDA asks for basic, clinical, and translational research on treatment of substance use disorder and overdose in people with HIV.
Medication optimization and interaction tools. NIA asks for optimizing medications and care coordination. NCCIH asks for evaluation of risks including drug and herb interactions. Polypharmacy in an ART-treated aging population is a well-defined software and decision-support problem.
Care coordination, clinical decision support, and digital delivery platforms. NIMH asks for scalable whole-person care models. NIDDK asks for strategies to improve implementation and delivery of evidence-based care. NIAMS prioritizes care models integrating musculoskeletal, rheumatic, and skin health into HIV settings.
Point-of-care coinfection testing. NIAID names tuberculosis, viral hepatitis, and sexually transmitted infections across the lifespan from infant through adult.
Integrated behavioral health and substance use interventions. NIDA names integrated interventions addressing HIV, substance use disorder, hepatitis C, and co-occurring mental health conditions. Digital therapeutics fit here.
Complementary and integrative health products and delivery. NCCIH names mind-body and natural product interventions for symptom clusters, plus pragmatic and hybrid effectiveness-implementation studies and scalable delivery models.
The test is the ordinary SBIR test, applied honestly: is there a commercial product with unresolved technical risk that your company will own and sell? If the deliverable is knowledge, a publication, or a care model your company will not commercialize, the mechanism is wrong even though the science is wanted.
Which Institute Should You Target?
With twelve awarding Institutes, the assignment request is the highest-leverage decision on the application. Group yourself by what you sell, not by the disease you are adjacent to.
If you build diagnostics, biomarkers, or screening tools: NHLBI for cardiopulmonary, cardiometabolic, hematologic, and sleep-disordered breathing detection, including subclinical detection and vascular contributions to cognitive impairment and dementia. NCI for cancer biomarkers, diagnostics, and early detection in people with HIV. NIDCR for oral and salivary gland complications and HPV-associated cancer detection, subject to the clinical trial restriction below. NIDDK for kidney, urologic, hematologic, liver, and metabolic conditions that present differently or follow altered courses in the context of HIV.
If you build therapeutics or biologics: NCI for HIV-related tumor pathogenesis and therapeutics. NIAID for tuberculosis, viral hepatitis, and sexually transmitted infection coinfections. NIAAA for approaches restoring alcohol-induced organ dysfunction across cardiovascular, metabolic, neurocognitive, and immune complications. NIDA for substance use disorder and overdose treatment in people with HIV. NIA for interventions addressing HIV-associated conditions in midlife and older age, framed against the NIH Stage Model from Stage 0 basic science through Stage V implementation.
If you build software, digital health, or care delivery platforms: NIMH for neurocognitive and mental health screening, early intervention, and scalable whole-person care models, including implementation research identifying diagnosis and treatment barriers. NIDA for care engagement, ART adherence, and access in underserved populations. NIA for care coordination and medication optimization. NIDDK for implementation and delivery of evidence-based care. NIAMS for whole-person care models integrating musculoskeletal and skin health, subject to the clinical trial restriction.
If you build complementary or integrative health products: NCCIH is the only door, and it is a good one. NCCIH frames HIV as a chronic multisystem condition with complex symptoms including pain, fatigue, and neurocognitive and mental health challenges, well suited to Whole Person Health approaches, and it stated it may give special consideration to meritorious applications here.
If your work concerns pediatric or perinatal populations: NICHD participates but published no areas of interest for this topic, listing only a scientific contact. The topic body does note that HIV-exposed but uninfected children may face elevated immune, metabolic, and developmental risks compared with unexposed peers, particularly in low and middle-income settings. If this is your space, the program officer call is not optional, because there is no published language to write against.
Quick reference: awarding Institutes and stated funding signals
NCCIH. Complementary and integrative health for symptom management. May give special consideration. Contact: Lanay Mudd, PhD, NCCIHDERFunding@nih.gov
NCI. Cancer risk, pathogenesis, prevention, diagnosis, treatment, and bundled cancer and HIV interventions. No stated signal. Contact: Rebecca Liddell Huppi, Ph.D.
NHLBI. Heart, lung, blood, and sleep comorbidity mechanisms and interventions. May dedicate available funds. Contact: nhlbihighlightedtopics@mail.nih.gov
NIA. HIV-associated conditions in midlife and older age across the NIH Stage Model. No stated signal. Contact: Marcel E. Salive, MD, MPH
NIAAA. Alcohol use and alcohol use disorder interactions with HIV pathophysiology and care. No stated signal. Contact: Kendall Bryant, Ph.D.
NIAID. Coinfections across the lifespan, with attention to stigma and health system factors. No stated signal. Does not accept clinical trials under STTR. Contact: Robin E. Huebner, PhD, MPH
NIAMS. Musculoskeletal, skin, and systemic rheumatic comorbidities, with priority to implementation science care models. No stated signal. Does not accept clinical trials under either parent. Contact: Heiyoung Park, PhD
NICHD. No published areas of interest for this topic. Contact: Sonia Lee, Ph.D.
NIDA. Drug use, addiction, and HIV interactions across the lifespan. May dedicate available funds and may give special consideration. The only Institute making both statements. Contact: NIDAHIVProgram@mail.nih.gov
NIDCR. Oral and craniofacial comorbidities and integration of oral health into HIV care. May give special consideration. Does not accept clinical trials under either parent. Contact: NIDCR-Program@nih.gov
NIDDK. Enteropathy and gastrointestinal homeostasis, liver disease and viral hepatitis coinfection, nutrition, obesity, diabetes, kidney, urologic, and hematologic disease. No stated signal. Does not accept clinical trials under STTR. Contact: Deepak Nihalani, Khoa Nguyen, Minnjuan Flournoy Floyd
NIMH. Neuropsychiatric mechanisms of CNS comorbidity, shared pathways, and implementation research. No stated signal. Contact: NIMH.DAR.inquiries@nih.gov
Which NIH Mechanism Should a Small Business Use?
Small businesses should apply through the NIH SBIR or STTR parent announcement and request assignment to the Institute whose interests match. On this topic the SBIR versus STTR choice carries unusual weight for two reasons: the topic actively encourages multidisciplinary academic collaboration, and the clinical trial restrictions differ between the two announcements.
NIH Parent SBIR, currently PA-27-100 (R43 and R44). The default route. Accepts Phase I, Phase II, Direct to Phase II, and Fast-Track. Use it when your company performs the majority of the research and your Principal Investigator is primarily employed by the company. Under PA-27-100, NIAMS and NIDCR do not accept clinical trial applications, and an application proposing a clinical trial that aligns only with one of those missions is non-responsive and will not be reviewed.
NIH Parent STTR, currently PA-27-102 (R41 and R42). Requires a formal collaboration with a nonprofit research institution, with at least 40 percent of the research at the small business and at least 30 percent at a single partner institution. STTR carries a feature that matters a great deal on this topic: the Program Director or Principal Investigator may be employed by either the small business or the partnering nonprofit, while the award still goes to the small business. For a company whose scientific lead is a clinician-researcher with a primary academic appointment, which describes much of the HIV comorbidity field, STTR is the only NIH small business mechanism that works. The tradeoff is a longer clinical trial exclusion list: under PA-27-102, NIAID, NIAMS, NIDCR, NIDDK, and NIMHD do not accept clinical trials.
The combined clinical trial picture for this topic. NIAMS and NIDCR accept no clinical trials under either parent, despite both asking for research that develops and tests interventions. NIAID and NIDDK accept clinical trials under SBIR but not under STTR, so a project with an academic PI and a trial component cannot use STTR at those Institutes. Review the NIH Clinical Trial Definition before assuming your study is not a trial, because it captures more designs than founders expect, including many behavioral and care delivery interventions that sit at the center of this topic.
Multiple Program Directors and Principal Investigators. The topic strongly encourages teams with multiple PD/PIs holding complementary expertise. NIH small business awards do permit multiple PD/PI structures, but the employment rules still bind. Confirm with your target Institute how the primary employment requirement applies across a multiple PD/PI team before you build the team into the application, because this is the point at which an otherwise strong interdisciplinary structure can become an eligibility problem.
Direct to Phase II. Available if you already hold the feasibility data a Phase I would generate and never received a Phase I award for that project. SBIR only, not available under STTR.
Fast-Track. Phase I and Phase II submitted together, reviewed once. Poor fit when Phase I results would change the Phase II design, which is common where the Phase I is a feasibility or usability study feeding an intervention design.
Phase IIB Strategic Breakthrough Award, currently PA-27-101 (R44). For companies that completed an NIH SBIR or STTR Phase II and need a commercialization bridge. Requires documentation of not less than 100 percent matching funds from new private capital or from a government source other than a Phase I or Phase II SBIR or STTR award. Award periods must not exceed 4 years. Budget guidance varies by Institute, and not all Institutes accept clinical trials through Phase IIB.
Commercialization Readiness Pilot, currently PAR-27-098 (SB1). Late-stage technical assistance and product development that Phase II and Phase IIB cannot support, including regulatory and reimbursement work. Permits more outsourcing, though the small business must retain substantial project management and oversight.
Funding Allowance
The ceiling depends on two layers, and with twelve participating Institutes the second layer is where the planning happens.
Layer one, the SBA statutory guidelines for the current cycle:
Phase I: up to $323,090 in total costs, for a project period of 6 months to 2 years
Phase II: up to $2,153,927 in total costs, for a project period of 1 to 3 years
Commercialization Readiness Pilot: up to $4,191,495 in total costs, for a project period of up to 3 years
Total funding support means direct costs, indirect costs, and fee combined. A reasonable profit or fee is allowable but must be in the budget at submission and normally will not exceed 7 percent of total costs. NIH does not adjust budgets after submission, so a request at the wrong level cannot be corrected later.
Layer two, Institute-specific guidance. NIH holds SBA waivers permitting awards above the guideline for approved topics, and each Institute publishes its own limits. For the participating Institutes here, the published picture as of this writing:
Higher Phase I headroom. The participating component table in the parent SBIR announcement lists Phase I limits above the statutory guideline for several Institutes in this topic, reaching $700,000 for the highest tier, which includes NCI, NIA, NIAID, NIMH, and NCCIH. Other components list $400,000, and some hold to the SBA guideline.
NCI. Publishes waiver-topic guidance generally funding Phase I up to $400,000 across up to 2 years and considering Phase II up to $2,250,000 across up to 3 years. NCI also runs a Phase IIB Bridge Award and caps its CRP support well below the government-wide figure.
NIDDK. Generally considers Phase I up to $350,000 across up to 2 years, Phase II up to $2,200,000 across up to 3 years, and Phase IIB up to $3,000,000, with Phase II and Phase IIB generally not exceeding $1,100,000 in any single year.
NIAAA. Publishes guidance that it will generally not fund Phase I applications to the omnibus above roughly $385,000 or Phase II awards above $3 million, even for topics on the SBA-approved waiver list.
NIAID. Publishes a per-year constraint rather than only a total: NIAID will not generally allow Phase II or Phase IIB awards of any duration exceeding $1,000,000 in total costs per year. This reshapes a budget more than a total-cost ceiling does.
NIDA. Publishes waiver-topic guidance permitting Phase II requests up to $2.5 million across up to 3 years where the research falls within its approved waiver topics and the justification is adequate.
NHLBI. Publishes its budget guidance through NOT-HL notices rather than a single standing page. Confirm the current notice with NHLBI program staff before budgeting.
NCCIH, NIA, NIAMS, NICHD, NIDCR, NIMH. Refer to the participating component table in the current parent announcement and confirm directly with program staff, as these Institutes do not all maintain standing published SBIR budget pages.
Two cautions. First, a ceiling in a component table is not the number that gets awarded. BW&CO's analysis of a fiscal year 2026 NCI SBIR award slice found Phase I level awards ranging from roughly $305,000 to $404,000, with not one award in 44 records reaching the $700,000 headroom. Budgeting to the ceiling budgets against an outcome that did not occur. Second, an Institute may reduce the recommended budget or shorten the award period for budgetary, administrative, or programmatic reasons even after a strong review score.
Timeline
The topic window runs from September 1, 2026 through July 28, 2028. That expiration is earlier than the usual two-year window and sits between two standard due dates, which removes a cycle other Highlighted Topics would offer.
Standard annual due dates: January 5, April 5, and September 5. When a due date falls on a weekend or federal holiday, NIH moves it to the next business day. Applications are due by 5:00 p.m. local time of the applicant organization.
Do not use the AIDS due dates. NIH runs a separate set of AIDS and AIDS-related receipt dates of January 7, May 7, and September 7 for many mechanisms, and researchers experienced with R01 submissions in this field will know those dates well. HHS SBIR and STTR grant applications are not accepted on the AIDS and AIDS-related due dates. The standard small business dates govern here despite the HIV subject matter. This is the most likely calendar mistake on this particular topic, and it is most likely to be made by an academic collaborator advising the team.
Cycles available under this topic:
September 2026 cycle: the September 5, 2026 date shifted to Tuesday, September 8, 2026 because of the weekend and the Labor Day holiday. Since the topic posted on September 1, this cycle is not realistically available.
January 5, 2027: the first realistic cycle for a company beginning preparation now.
April 5, 2027
September 5, 2027
January 5, 2028
April 5, 2028, the final cycle. The topic expires July 28, 2028, before the September 2028 date.
What the runway looks like: plan on roughly 9 months from submission to funds in the door. An application submitted in the January 2027 cycle typically reaches an earliest possible start date in the fall of 2027. Council decisions for the September and January cycles are often handled together, so deferring a cycle is not costless.
Work backwards from your target date:
16 to 18 weeks out: identify your target Institute, confirm its clinical trial policy for your chosen mechanism, contact program staff, and start or verify federal registrations. This topic warrants a longer lead time than most because of the Institute selection and clinical trial questions.
12 weeks out: lock the Specific Aims page, confirm the multiple PD/PI structure against employment rules, and circulate to program staff
8 weeks out: complete the research strategy, commercialization plan, letters of support, community partner documentation, and any IRB or human subjects planning
4 weeks out: full internal review, budget finalization, and subaward paperwork for any STTR or academic partner
1 week out: submit early to leave room for eRA Commons error correction
Registrations are the most common cause of a missed deadline. You need SAM.gov with a Unique Entity ID, the SBA Company Registry, eRA Commons, and Grants.gov. eRA Commons access depends on the SBA Company Registry being complete first. Allow six weeks or more and begin before you write.
Also note that the current SBIR parent, PA-27-100, closes in early April 2027, well before this topic expires. Applicants targeting later cycles must confirm the active announcement number at the time of submission.
Detailed Overview of What NIH Is Looking For
The problem NIH is trying to solve
The topic opens from a position of success. Antiretroviral therapy has transformed HIV into a manageable chronic condition. The consequence is a new problem: people with HIV face high risk and early onset of comorbidities, ART-related adverse effects, and interconnected medical, psychosocial, and structural challenges. The scope extends beyond people with HIV themselves. The topic notes that HIV and its treatment may also affect individuals exposed to HIV, and that HIV-exposed, uninfected children may face elevated immune, metabolic, and developmental risks compared with unexposed, uninfected peers, particularly in low and middle-income settings.
The named gap is mechanistic and specific: how HIV, ART, and psychosocial stressors interact to drive early onset and progression of comorbidities. NIH argues that many comorbidities involve intersecting pathways and shared risk factors even as they diverge into disease-specific trajectories, giving two examples. Metabolic syndrome increases risk for diabetes, cardiovascular disease, and chronic kidney disease. Certain coinfections increase cancer risk. Elucidating the shared factors, NIH argues, may inform preventive strategies addressing multiple outcomes at once.
The methodological critique follows from that. Traditional disease-specific models may insufficiently capture shared factors or multilevel implementation determinants. NIH instead points toward comprehensive whole-person care linking infectious diseases, endocrinology, psychiatry, nursing, pharmacy, and community health, with emphasis on early screening, lifestyle-based prevention, and sustained engagement in HIV care, while requiring careful attention to local context and health system factors for effective implementation.
Read strategically, that argument creates a specific opening for a product company. If NIH believes the shared upstream factors matter more than the disease-specific endpoints, then a screening tool, biomarker panel, or decision-support system that detects or manages a shared factor across multiple downstream comorbidities is more responsive than one addressing a single condition. A cardiometabolic risk platform that also informs kidney and cancer risk is speaking the topic's language. A single-indication tool is not.
The stated purpose
The topic aims to catalyze interdisciplinary research on HIV-associated co-occurring conditions and to expand multidisciplinary teams that develop and deliver preventive strategies improving health and quality of life for people with HIV across the lifespan. Emphasis falls on two things: research on shared factors and multi-organ effects to inform early preventive strategies, and implementation science approaches that identify barriers and facilitators, optimize multidisciplinary care approaches, and deliver scalable, sustainable care models. Multidisciplinary teams with multiple Program Directors and Principal Investigators holding complementary expertise in HIV and relevant conditions, cross-NIH alignment, and use of existing resources are all strongly encouraged.
Two phrases in that paragraph carry weight for a small business. "Scalable, sustainable care models" is commercialization language, and it invites a business model argument about who pays and how the model persists after grant funding ends, which most academic applications will answer weakly. "Use of existing resources" points toward NIH cohorts, data platforms, and networks, and a company that proposes to validate against an existing NIH resource rather than build a new cohort is both cheaper and more responsive.
Selected Institute areas of interest, with strategic reads
NHLBI seeks mechanisms and pathways contributing to HIV-associated heart, lung, blood, and sleep comorbidities, and interventions that improve care including implementation evaluation. Its named priorities are the combined effects of aging, HIV, and ART on those conditions; aging and HIV-related changes in hematopoiesis including hematopoietic stem cells and their niche; the impact of sleep deficiency and sleep-disordered breathing on HIV-associated cardiopulmonary and cardiometabolic disease pathogenesis; vascular contributions to cognitive impairment and dementia; implementation strategies improving uptake and sustainability of evidence-based interventions; mechanistic studies reducing the effects of HIV and aging including traditional risk factors and sex differences; and novel methods to detect subclinical HIV-related conditions plus strategies to mitigate clinical disease.
Read: the last bullet is the strongest product invitation in the topic. Subclinical detection is a diagnostics problem with a defined customer and a regulatory pathway. NHLBI also stated it may dedicate available funds. Sleep-disordered breathing is a notable inclusion for wearable and home-testing companies.
NCI seeks advancement in understanding risks, development, progression, prevention, diagnosis, and treatment of cancer in people with HIV, plus testing and implementation of bundled cancer and HIV interventions. It notes that people with HIV have increased incidence of certain cancers, are diagnosed later at higher stage, have worse overall and cancer-specific survival, and are less likely to receive cancer treatment. Its example topics are characterizing HIV's contribution to HIV-related tumor development and pathogenesis; discovering and developing new biomarkers, diagnostics, and therapeutics; and identifying factors influencing cancer disparities including improving adoption, implementation, and sustainment of effective interventions.
Read: "bundled cancer/HIV interventions" is unusual phrasing and signals interest in combined care products rather than single-purpose tools. The treatment access disparity NCI names is a care delivery problem as much as a clinical one.
NIDA seeks interdisciplinary research on how drug use, addiction, and HIV interact across the lifespan, spanning brain function, behavior, mood, sleep, pain, and cognition under HIV, ART, and polysubstance use; molecular, neurochemical, cellular, and circuit function underpinning HIV and co-occurring substance use disorders; shared pathways linking substance use, HIV, stress, trauma, and mental health; individual and community factors affecting prevention, care engagement, and ART adherence with focus on improving access in underserved populations; integrated interventions addressing HIV, substance use disorder, hepatitis C, and co-occurring mental health conditions; and basic, clinical, and translational research on substance use disorder and overdose treatment in people with HIV.
Read: NIDA is the only Institute here making both funding statements, and its list is unusually accommodating, spanning basic neuroscience through digital adherence tools through overdose therapeutics. If your product plausibly fits NIDA, that combination of breadth and stated signal makes it the strongest default target on this topic.
NCCIH supports complementary and integrative health approaches for symptom management, prioritizing testing of interventions such as mind-body and natural products to address symptom clusters and improve function and quality of life; elucidating biological, behavioral, and psychosocial mechanisms including inflammation, neuroimmune, and stress pathways and identifying biomarkers and patient characteristics; integrating these approaches into HIV care through pragmatic and hybrid effectiveness-implementation studies and scalable delivery models; and evaluating risks such as drug and herb interactions, synthesizing evidence, and developing decision-making guidance.
Read: the risk evaluation and guidance bullet is the least crowded. A drug and herb interaction screening tool for an ART-treated population is a clean software product with a real safety rationale, and NCCIH stated it may give special consideration.
NIAMS and NIDCR both ask for interventions while accepting no clinical trials. NIAMS seeks research on HIV-associated musculoskeletal, skin, and systemic rheumatic comorbidities including musculoskeletal pain, sarcopenia and cachexia, cartilage degeneration and osteoarthritis, osteoporosis and fractures, arthritis and rheumatic disease, and dermatologic manifestations, and states that priority is given to implementation science projects developing, testing, and scaling multidisciplinary whole-person care models. NIDCR seeks mechanisms of HIV-related oral disease; biological, behavioral, and contextual risk factors linking oral and systemic comorbidities including HPV-associated cancer; interdisciplinary preventive, diagnostic, and treatment approaches including probiotics, mucosal immunity modifiers, and early cancer detection; and integration of oral health into the HIV care continuum.
Read: this is the sharpest trap on the page. Both Institutes invite intervention development and both are on the clinical trial exclusion list for the parent announcements. The workable path is a project whose endpoints are technical, mechanistic, or feasibility-based rather than a trial testing safety or efficacy in human subjects, or a submission through an Institute-specific announcement designed for trials. Confirm the design with program staff before drafting, not after.
NIA, NIAAA, NIAID, NIDDK, and NIMH round out the awarding set. NIA works across the NIH Stage Model from Stage 0 basic science through Stage V implementation, interested in etiology and pathogenesis including chronic immune activation and antiretroviral and other drug toxicities, optimizing medications and care coordination alongside behavioral and social interventions, and developing, testing, implementing, and scaling evidence-based interventions. NIAAA focuses on heavy alcohol use and alcohol use disorder, noting it accelerates physiological vulnerability, impacts medication adherence and toxicities, and complicates care, with complications including cardiovascular disease, metabolic disorders, neurocognitive impairment, and cellular and immune dysfunction. NIAID focuses on coinfections from infant through adult, encouraging attention to stigma and intersecting behavioral, biological, and health system factors in diagnosing, preventing, and treating tuberculosis, viral hepatitis, and sexually transmitted infections. NIDDK spans enteropathy and gastrointestinal homeostasis, liver disease and viral hepatitis coinfection, digestive disease, nutrition, obesity, diabetes and complications, and kidney, urologic, and hematologic disease presenting differently under HIV, and gives high priority to studies of social, behavioral, and environmental factors affecting disease severity and treatment adherence. NIMH focuses on neuropsychiatric mechanisms of CNS comorbidity, how HIV biology, treatment exposures, and psychosocial burden converge on shared pathways driving neurocognitive and mental health disorders, and multidisciplinary implementation research identifying diagnosis and treatment barriers with emphasis on community engagement and sustainable delivery.
What the non-awarding offices add
Five offices participate without awarding grants: the Office of AIDS Research, which also serves as the central scientific contact for the topic; the Office of Behavioral and Social Sciences Research; the Office of Disease Prevention; the Office of Research on Women's Health; and the Tribal Health Research Office. Your application must be relevant to the objectives of at least one awarding Institute, and their interests function as additional strength rather than an independent route.
OAR is interested in interdisciplinary research including implementation science advancing understanding of common factors underlying HIV-associated co-occurring conditions, supporting early prevention, integrated whole-person care, and improved health and quality of life across the lifespan. ODP is particularly interested in innovative prevention research using rigorous study design, measurement, and analysis methods to test interventions, implementation strategies, and multidisciplinary care approaches. ORWH is interested in projects addressing HIV-associated co-occurring conditions in women. OBSSR and THRO participate without publishing specific interests for this topic.
Practical read: ODP's emphasis on rigorous design, measurement, and analysis is the most actionable of these, because methodological rigor is cheap to strengthen and is where small business applications most often lose points. Powering your study properly and pre-specifying your analysis is a low-cost, high-return decision. OAR being the central contact also means a single call to OAR can help route you among twelve Institutes if you are genuinely unsure where you fit.
MAHA alignment
This topic is issued as part of the Make America Healthy Again initiative and lists eight named alignments, more than any comparable topic: the NIH MAHA Chronic Disease Initiative's Whole-Person-Health approach; Food for Health, a joint HHS, VA, and USDA effort studying food and lifestyle interventions and their cost impact, coordinated by the NIH Office of Nutrition and including large-scale randomized controlled trials; Nutrition, spanning NIH partnership with FDA, USDA, and the Administration for a Healthy America, expanded research on dietary patterns supporting metabolic health, the FDA and NIH Joint Nutrition Regulatory Science Program, and precision nutrition; the Oral Health and Systemic Disease Connection, examining pediatric oral health links to cardiovascular disease, diabetes, and autoimmune conditions plus oral microbiome relationships with gut health and immune function; the Gut Microbiome Research Initiative; Longitudinal Research for Chronic Disease Prevention, naming the Adolescent Brain Cognitive Development Study, the Healthy Brain and Child Development Study, All of Us, and the Environmental Influences on Child Health Outcomes Program, with example areas including sleep, nutrition, insulin resistance, select high-quality supplements, and fitness as a vital sign; and Mental Health and Addiction Research, with a special focus on screentime in children and adolescents.
Practical read: pick one or two, not eight. The named longitudinal resources are the most useful, because "use of existing resources" is explicitly encouraged in the topic purpose, and proposing validation against All of Us or a named cohort is concrete, cheaper than new recruitment, and directly responsive. For a nutrition or metabolic product, Food for Health and the Nutrition alignment are the natural anchors. For oral health, NIDCR plus the Oral Health and Systemic Disease Connection is a coherent pairing.
Eligibility Requirements
To apply for an NIH SBIR or STTR award, your company must meet the core SBA criteria:
Organized for profit, with a place of business located in the United States, and the primary research performed in the United States
More than 50 percent directly owned and controlled by one or more individuals who are U.S. citizens or permanent resident aliens, by other for-profit small business concerns each majority owned by such individuals, or by a combination. Certain venture capital, hedge fund, and private equity structures may qualify for SBIR under specific conditions, and Tribal, Alaska Native Corporation, Native Hawaiian Organization, and joint venture paths exist. Complex cap tables should be checked against 13 CFR Part 121.
No more than 500 employees including all affiliates. A subsidiary counts its parent's employees.
For SBIR, the Principal Investigator's primary employment must be with the small business at the time of award and for the duration of the project. For STTR, the PD/PI may be primarily employed by either the small business or the partnering nonprofit research institution, with the award still made to the small business.
For SBIR Phase I, the small business must perform at least two thirds of the research or analytical effort. For SBIR Phase II, at least half. For STTR, the small business performs at least 40 percent and a single partner nonprofit research institution performs at least 30 percent.
Additional constraints that matter on a topic this broad. NIH will not accept similar applications with essentially the same research focus from the same applicant organization, including derivative applications proposing a single product that can be applied to multiple purposes with non-substantive modification. You may not simultaneously submit identical or essentially identical applications under both parent announcements. Duplicate or highly overlapping applications under simultaneous review are not accepted. Applicants must disclose overlapping federal work under the essentially equivalent work rule. Companies with a substantial award history should confirm they meet the Phase I to Phase II Transition Rate and commercialization benchmarks, which can restrict new Phase I, Fast-Track, and Direct to Phase II eligibility for one year. Heightened screening of foreign ownership and foreign influence applies under the 2026 reauthorization, with additional scrutiny possible for STTR because of the research institution partnership.
What a Competitive Application Looks Like
A shared-factor story, not a single-condition story. The topic's central argument is that comorbidities share upstream pathways and risk factors. A product addressing a shared factor with consequences across multiple downstream conditions is answering the question asked. A single-indication tool is answering a different one.
The right Institute, confirmed by a call. Twelve awarding Institutes with different missions, different budget ceilings, and different clinical trial policies. The program officer conversation determines assignment, budget realism, and whether your design is even reviewable. On this topic that call is worth more than on almost any other.
A clinical trial determination made early. Review the NIH Clinical Trial Definition against your actual design before choosing a mechanism and Institute. Behavioral and care delivery interventions frequently meet the definition when founders assume they do not, and NIAMS, NIDCR, NIAID, and NIDDK all carry restrictions.
Validation against existing NIH resources. The topic explicitly encourages use of existing resources, and the MAHA alignment names specific longitudinal cohorts. Proposing to validate against an existing resource is cheaper, faster, and more responsive than proposing new recruitment.
A sustainability and payer argument, not just a care model. The topic asks for scalable, sustainable care models. For a company that means naming who pays after the grant ends: reimbursement pathway, health system purchaser, or payer. Academic applications will treat sustainability as an aspiration. Treating it as a business model is your advantage.
Community engagement that is documented, not asserted. Meaningful community engagement is strongly encouraged throughout the topic. Letters, agreements, and named partners carry weight. A stated intention does not.
An interdisciplinary team that survives the eligibility rules. Multiple PD/PIs with complementary expertise are encouraged, but SBIR employment rules still bind. Build the team and confirm the structure with program staff in the same step.
Common Reasons Applications Miss
Treating the Highlighted Topic as a NOFO and searching Grants.gov for a topic-specific number that does not exist
Submitting on an AIDS due date of January 7, May 7, or September 7, which HHS does not accept for SBIR or STTR applications
Proposing a clinical trial to NIAMS or NIDCR, which accept none under either parent announcement, making the application non-responsive and unreviewed
Proposing a clinical trial to NIAID or NIDDK through STTR, which neither accepts, when SBIR would have worked
Assuming a behavioral or care delivery intervention is not a clinical trial without checking the NIH Clinical Trial Definition
Pursuing SBIR when the scientific lead holds a primary academic appointment, where STTR permits that PD/PI arrangement and SBIR does not
Bringing an academic research project to a small business mechanism, where the deliverable is knowledge rather than a commercial product the company will own and sell
Targeting NICHD without a program officer conversation, since NICHD published no areas of interest for this topic
Budgeting to the $700,000 Phase I ceiling rather than the roughly $400,000 that Institutes actually award, or ignoring NIAID's per-year constraint of $1,000,000 in total costs
Omitting the fee from the budget or requesting the wrong level, neither correctable after submission
Citing all eight MAHA alignments rather than the one or two that fit, which reads as unfocused
Starting federal registrations after drafting begins, then missing the receipt date on an eRA Commons validation error
Frequently Asked Questions
Is this a grant I can apply to directly?
No. This is an NIH Highlighted Topic, which is a statement of scientific priority rather than a Notice of Funding Opportunity. You apply through a broad NIH announcement, and for small businesses that means the NIH SBIR or STTR parent announcement, requesting assignment to one of the twelve awarding Institutes.
Which funding opportunity number do I actually use?
For most small businesses it is PA-27-100, the NIH, CDC, and FDA Parent SBIR announcement covering R43 and R44 awards. If your project depends on a formal university or nonprofit research partner, use PA-27-102, the Parent STTR announcement covering R41 and R42. Confirm the active number at submission, since PA-27-100 closes in early April 2027 while this topic runs to July 2028.
When is the deadline, and do the AIDS due dates apply?
There is no deadline specific to this topic. You submit on the NIH standard small business receipt dates of January 5, April 5, and September 5, with dates falling on weekends or federal holidays moving to the next business day. The AIDS and AIDS-related due dates of January 7, May 7, and September 7 do not apply, because HHS does not accept SBIR or STTR grant applications on those dates. The topic expires July 28, 2028, making April 5, 2028 the final available cycle.
Which of the twelve Institutes should I target?
Group by what you sell. Diagnostics and screening point to NHLBI, NCI, NIDCR, or NIDDK. Therapeutics point to NCI, NIAID, NIAAA, NIDA, or NIA. Software and care delivery point to NIMH, NIDA, NIA, NIDDK, or NIAMS. Complementary and integrative health points to NCCIH. NIDA is the only Institute that stated both that it may dedicate funds and that it may give special consideration, which makes it a strong default where the fit is genuine.
How much money can my company request?
The SBA statutory guidelines this cycle are $323,090 for Phase I and $2,153,927 for Phase II in total costs, including direct costs, indirect costs, and fee. Institute limits differ substantially. Several Institutes in this topic list Phase I headroom to $700,000, NCI publishes waiver guidance near $400,000 for Phase I and $2,250,000 for Phase II, NIDDK publishes $350,000 and $2,200,000, NIAAA caps near $385,000 and $3 million, and NIAID applies a per-year constraint of $1,000,000 in total costs on Phase II and Phase IIB. Confirm with your target Institute before setting a budget.
Can I include a clinical trial in my application?
It depends entirely on the Institute and the mechanism. Under the parent SBIR announcement, NIAMS and NIDCR do not accept clinical trials. Under the parent STTR announcement, NIAID, NIAMS, NIDCR, NIDDK, and NIMHD do not. An application proposing a clinical trial that aligns only with an excluded component is non-responsive and will not be reviewed. Check the NIH Clinical Trial Definition against your design first, because many behavioral and care delivery interventions meet it.
My scientific lead is a university faculty member. Can we still apply?
Yes, through STTR. Under the parent STTR announcement the Program Director or Principal Investigator may be primarily employed by either the small business or the partnering nonprofit research institution, while the award still goes to the small business. SBIR requires the PI's primary employment to be with the company. Given how much of the HIV comorbidity field sits in academic clinical settings, this is often the deciding factor on mechanism.
The topic encourages multiple Principal Investigators. Does SBIR allow that?
NIH small business awards do permit multiple Program Director and Principal Investigator structures, but the employment requirements still apply. Because the interaction between a multi-PI team and the primary employment rule can create an eligibility problem, confirm the specific structure with your target Institute's program staff before building the team into the application.
How long until I receive funding?
Plan on approximately 9 months from submission to award start. An application submitted in the January 2027 cycle would typically have an earliest possible start date in the fall of 2027.
Do I have to give up equity or match the funds?
No. NIH SBIR and STTR Phase I and Phase II awards are non-dilutive and require no cost share. The exception is the Phase IIB Strategic Breakthrough Award, which requires not less than 100 percent matching funds from new private capital or from a government source other than a Phase I or Phase II SBIR or STTR award.
Is this topic really a fit for a small business, or is it academic research?
Both, and the distinction matters. Cohort analysis, mechanistic basic science, epidemiological characterization, and academically led community trials belong in R01 and related mechanisms. Genuine small business lanes include subclinical disease detection, biomarkers and diagnostics, therapeutics, medication optimization and drug interaction tools, care coordination and clinical decision support software, point-of-care coinfection testing, and integrated behavioral health delivery platforms. The test is whether there is a commercial product with unresolved technical risk that the company will own and sell.
Does any Institute set aside dedicated funding for this topic?
Not guaranteed, but four made statements. NIDA stated both that it may dedicate available funds and that it may give special consideration. NHLBI stated it may dedicate available funds. NCCIH and NIDCR each stated they may give special consideration. The remaining eight awarding Institutes made neither statement. Treat these as a favorable tilt rather than a reserved pool.
Why does NICHD list no areas of interest?
NICHD participates in this topic but published only a scientific contact rather than stated interests. The topic body does note elevated immune, metabolic, and developmental risks in HIV-exposed but uninfected children, particularly in low and middle-income settings. With no published language to write against, a program officer conversation is essential before investing in a NICHD-targeted application.
I already have feasibility data. Do I still need a Phase I?
Not necessarily. SBIR Direct to Phase II allows a company that has demonstrated the scientific and technical merit and feasibility normally expected from a Phase I, without having received a Phase I award for that project, to apply directly for Phase II. This authority is available for SBIR only and is not available under STTR.
Do OAR, OBSSR, ODP, ORWH, and THRO award grants?
No. All five participate without awarding. Your application must be relevant to the objectives of at least one awarding Institute. OAR does serve as the central scientific contact for the topic, which makes it a useful first call if you are unsure which of the twelve Institutes fits your technology.
What registrations do I need, and how long do they take?
SAM.gov with a Unique Entity ID, the SBA Company Registry, eRA Commons, and Grants.gov. eRA Commons access depends on completing the SBA Company Registry first, so the sequence matters. Allow at least six weeks, and start before you begin writing.
How BW&CO Helps
BW&CO is a non-dilutive federal funding advisory firm. We help deep-tech, biotech, medtech, and health technology founders convert agency priority signals like this one into funded awards.
This topic has twelve awarding Institutes, four different clinical trial policies, and budget ceilings that range from the statutory guideline to $700,000 at Phase I. Most of the value is created before drafting begins: honest fit assessment, Institute selection and assignment strategy, clinical trial determination and mechanism choice, program officer engagement, multi-PI structure review against eligibility rules, Specific Aims development, full proposal build, budget and fee construction, commercialization and sustainability planning, and Phase IIB matching capital positioning. Our team has helped clients secure more than $350 million in funding. Innovation Funding Simplified.
If you are building a product for people with HIV and want a straight answer on whether this topic fits your company, which Institute to target, and whether you are competitive for the January 5, 2027 cycle, contact us for a fit assessment.
